1. Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002;122:512-30.
2. Reinisch W, Rutgeerts P, Panaccione R, D'Haens G, et al. Identifying appropriate dichotomizing points for SES-CD to predict long-term clinical remission for adalimumab-treated patients with Crohn's disease. J Crohns Colitis. 2010;4:P045.
3. Vorobyov G.I., Khalif I.L. Inflammatory bowel diseases. Miklosh, 2008. (In Russ.).
4. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307-17.
5. Ivashkin V.T., Lapina T.L. Gastroenterology. National recommendations. GEOTAR Media, 2008. 754p. (In Russ.).